W. Musiał

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

The association between type 2 diabetes mellitus and A1/A2 polymorphism of glycoprotein IIIa gene

K. Kamiński, B. Szepietowska, J. Janica, 2007, Acta Diabetologica.

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.

J. De Sutter, R. Peters, S. Wiedmann, 2019, Atherosclerosis.

[Resistance to therapy in primary nephrotic syndrome: effect of MDR1 gene activity].

M. Zaniew, C. Zanker, J. Maciejewski, 2000, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

DRD4 Exon 3 Gene Polymorphisms in Patients Diagnosed with Polysubstance Use Disorder and Co-Occurrence of a Depressive Episode

J. Masiak, Jolanta Chmielowiec, A. Grzywacz, 2021, Genes.

Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as predictor for coronary atherosclerosis.

I. Kowalska, W. Kochman, B. Telejko, 2001, Diabetes care.

Plasma adiponectin and E-selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism.

M. Górska, I. Kowalska, M. Strączkowski, 2006, Advances in medical sciences.